Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics

描述（由申请人提供）：作为两个nci指定的综合性癌症中心，威斯康星大学卡本癌症中心（UWCCC）和新泽西罗格斯癌症研究所（CINJ）已经证明了领导力，强大的基础设施，以及合作开展临床试验的良好记录。因此，UWCCC和CINJ成立了威斯康星和新泽西精密实验治疗联盟（WIN-Alliance），其使命是在多学科和多机构模式下开发和评估创新的早期实验治疗临床试验。科学优势包括强调生物标志物开发的翻译；药物基因组学的评估;基因组评估和治疗；临床和组织成像；以及系统生物学。在组织上，我们已经成立了工作组，利用科学专业知识和中心共享资源的基础设施优势来优先考虑ET-CTN的工作。win联盟独有的特定利基包括UWCCC强有力的PK/PD努力，已经为CTEP/U01临床试验增加了价值；UWCCC和CINJ的互补成像优势；使用Rutgers University Cell and DNA Repository （RUCDR）进行基因组分析；以及CINJ与高级研究所西蒙斯系统生物学中心的关系。在过去的五年中，UWCCC和CINJ在所有治疗试验中积累了4,000多名患者，为NCI-CTEP开发了67项中心科学驱动的提案，平均每年为UOl支持的研究积累了100名目标患者。具体目标是：1)开发和开展ET-CTN资助的新型抗癌药物的早期临床试验；2)利用和协同中心规划研究领域和核心，将实验室的科学发现转化为临床试验；3)发展一体化、一体化

DESCRIPTION (provided by applicant): As two NCI-designated comprehensive cancer centers that were collaborative as prior UOl sites, the University of Wisconsin Carbone Cancer Center (UWCCC) and Rutgers Cancer Institute of New Jersey (CINJ) have proven leadership, a robust infrastructure, and a strong record of conducting clinical trials collaboratively. UWCCC and CINJ have, therefore, formed the Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics (WIN-Alliance) with a mission to develop and evaluate innovative early phase experimental therapeutic clinical trials in a multi-disciplinary and multi-institutiona model. Scientific strengths include a translational emphasis with biomarker development; pharmacogenomic assessment; genomic assessment and treatment; clinical and tissue imaging; and systems biology. Organizationally, we have formed working groups that leverage scientific expertise and infrastructural strengths from center shared resources to prioritize ET-CTN efforts. Specific niches unique to the WIN-Alliance include strong PK/PD efforts at UWCCC already adding value to CTEP/U01 clinical trials; complementary imaging strengths at UWCCC and CINJ; genomic analysis using the Rutgers University Cell and DNA Repository (RUCDR); and CINJ's relationship with the Institute for Advanced Study's Simons Center for Systems Biology. Over the past five-years UWCCC and CINJ accrued over 4,000 patients on all therapeutic trials, developed 67 center science driven proposals to NCI-CTEP, and accrued a mean of the targeted 100 patients/yr to the UOl supported studies. The specific aims are to: 1) develop and perform early clinical trials with new ET-CTN sponsored anti-cancer agents; 2) leverage and synergize with center programmatic areas of research and cores to translate scientific discoveries from the laboratory into clinical trials; 3) develop integrated and integral genomic, pharmacogenomics, pharmacokinetic, and pharmacodynamic biomarkers; 4) develop integral and integrated novel approaches to clinical and tissue imaging; and, 5) train and develop young investigators in translational research. RELEVANCE: This application will merge two strong prior Phase I (UOl) sites to create the Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics (WIN-Alliance). This group, as a synergistic, multidisciplinary and multi-institutional model, will develop and evaluate innovative, early phase experimental therapeutic clinical trials to improve clinical outcomes.